TickerWorth Open the interactive view →

Nanobiotix S.A. (NBTX) — Available-Data Snapshot

Updated Nov 10, 2026 · available-data snapshot · descriptive, not a DCF, not advice

Price
$32.03
Market cap
$1,631,784,064
52-week high
$57.14
52-week low
$19.14
Currency
USD
Exchange
NasdaqGS

We don't publish a discounted-cash-flow fair value for Nanobiotix S.A. (NBTX) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.

On the numbers we do have, NBTX trades at a recent price of $32.03, a market capitalisation of about $1,631,784,064, sitting 34% of the way up its 52-week range ($19.14–$57.14), on the NasdaqGS.

The standard alternative to a DCF is relative valuation — comparing NBTX's trading multiples against a sector benchmark. Here that gives P/S of 141.8× (richer than the peer median of 6.8×). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.

Finally, a price-based read — explicitly not a valuation. NBTX is in a mixed trend, trading -43.9% from its 52-week high. Over the past year the stock is +38.2%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.

Relative valuation — NBTX vs peers

MultipleNBTXPeer median
P/S141.8×6.8×richer than

Sector benchmark (bellwethers, not direct competitors).

Asset / book-value view

We are not showing a price-to-book for this listing: the book value we have does not belong to the same share class as the price, so any ratio of the two would be arithmetic rather than a valuation.

Price-based snapshot

50-day avg
$31.18
200-day avg
$34.06
From 52-wk high
-43.9%
1-year momentum
+38.2%

Price-based, not a valuation. Moving-average trend and 52-week position describe where the stock has traded — they say nothing about fair value.

Explore more

Most undervalued stocks (per our valuation) · All valued stocks · Interactive NBTX view

A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is an educational tool, not a licensed investment adviser. Figures are estimates derived from public market data and can be wrong, stale or incomplete.